Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
1.420
-0.170 (-10.69%)
Mar 31, 2025, 9:30 AM EST - Market open

Channel Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-7.96-7.38-2.46-0.6-0.66
Other Amortization
0.690.190.14--
Stock-Based Compensation
1.81.730.11--
Other Operating Activities
-0.362.43--0.24-
Change in Accounts Payable
1.181.630.41-0.83-2.97
Change in Other Net Operating Assets
-1.140.420.230.07-
Operating Cash Flow
-5.79-0.98-1.57-1.59-3.63
Short-Term Debt Issued
0.540.770.4-0.24
Long-Term Debt Issued
--0.81.1-
Total Debt Issued
0.540.771.21.10.24
Short-Term Debt Repaid
-0.21----
Total Debt Repaid
-0.21----
Net Debt Issued (Repaid)
0.320.771.21.10.24
Issuance of Common Stock
6.050.260.420.493.38
Repurchase of Common Stock
-0.08----
Other Financing Activities
-0.09----
Financing Cash Flow
6.211.021.621.593.63
Net Cash Flow
0.420.040.06--
Levered Free Cash Flow
-8.76-0.64---
Unlevered Free Cash Flow
-8.96-0.5---
Change in Net Working Capital
4.23-2.05---
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q